IDenta Corp. (IDTA)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
IDenta Corp. (IDTA) with AI Score 56/100 (Hold). IDenta Corp. specializes in developing and manufacturing field detection and home diagnostic testing kits for narcotics, explosives, and forensic products. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 15, 2026IDenta Corp. (IDTA) Healthcare & Pipeline Overview
IDenta Corp., based in Israel, develops and supplies narcotics and explosives detection kits, catering to law enforcement and security sectors worldwide. With a focus on field-portable solutions, the company addresses the growing need for rapid on-site testing in homeland security and consumer markets, operating with a negative profit margin of -5.4%.
Investment Thesis
IDenta Corp. presents a focused play on the growing demand for rapid narcotics and explosives detection solutions. The company's specialized product line caters to a niche market within the homeland security and law enforcement sectors. With a market capitalization of $0.00B and a negative P/E ratio of -12.21, the company's valuation reflects its current financial challenges. Key growth catalysts include potential partnerships with government agencies and expansion into new geographic markets. However, investors should be aware of the risks associated with the company's OTC listing and limited financial resources. The company's gross margin of 29.8% indicates potential for profitability improvements through increased sales and operational efficiencies. The beta of 0.48 suggests lower volatility compared to the overall market.
Based on FMP financials and quantitative analysis
Key Highlights
- Market Cap of $0.00B reflects the company's small size and limited investor interest.
- P/E Ratio of -12.21 indicates that the company is currently not profitable.
- Profit Margin of -5.4% highlights the challenges in achieving profitability.
- Gross Margin of 29.8% suggests potential for profitability with improved efficiency.
- Beta of 0.48 indicates lower volatility compared to the overall market.
Competitors & Peers
Strengths
- Specialized product line for narcotics and explosives detection.
- Proprietary testing technologies.
- Established relationships with law enforcement agencies.
- Expertise in forensic product development.
Weaknesses
- Small market capitalization.
- Negative profit margin.
- Limited financial resources.
- OTC listing.
Catalysts
- Potential partnerships with law enforcement agencies to supply testing kits.
- Expansion into emerging markets with high demand for security solutions.
- Development and commercialization of new testing technologies.
- Launch of home diagnostics testing kits for drugs and other substances.
- Increased adoption of portable sniffer technology in various settings.
Risks
- Competition from larger and more established players in the diagnostics and security sectors.
- Evolving security threats requiring continuous innovation and adaptation.
- Regulatory changes impacting testing requirements and market access.
- Economic downturn affecting government spending on security and law enforcement.
- Limited financial resources and negative profit margin.
Growth Opportunities
- Expansion into Emerging Markets: There is a significant opportunity for IDenta to expand its presence in emerging markets where the demand for security and narcotics detection is growing. These markets often have less stringent regulatory environments, allowing for faster market entry. A targeted approach focusing on specific regions with high demand could drive revenue growth. The timeline for this expansion is estimated at 2-3 years, with potential for significant revenue contribution.
- Partnerships with Law Enforcement Agencies: Collaborating with law enforcement agencies at the local, national, and international levels can provide IDenta with a stable revenue stream and enhanced credibility. These partnerships can involve supplying testing kits, providing training, and developing customized solutions. Securing long-term contracts with these agencies can ensure consistent demand and market penetration. This opportunity can be realized within the next 1-2 years.
- Development of New Testing Technologies: Investing in research and development to create new and improved testing technologies can provide IDenta with a competitive edge. This includes developing more sensitive and accurate detection methods, as well as expanding the range of substances that can be detected. Staying ahead of emerging threats and adapting to evolving security needs is crucial for long-term success. The timeline for developing and commercializing new technologies is estimated at 3-5 years.
- Focus on Home Diagnostics Market: Expanding into the home diagnostics market with easy-to-use testing kits for drugs and other substances can tap into a new customer base. This requires developing products that are user-friendly and affordable, as well as establishing distribution channels through retail stores and online platforms. The potential market size for home diagnostics is substantial, offering significant growth opportunities. This expansion can be initiated within the next 1-2 years.
- Leveraging Portable Sniffer Technology: IDenta's portable sniffer technology offers a unique advantage in the field of narcotics and explosives detection. By further developing and refining this technology, the company can create more advanced and versatile sniffers that can be used in a variety of settings. This includes developing sniffers that can detect trace amounts of substances and operate in challenging environments. The timeline for enhancing and commercializing this technology is estimated at 2-3 years.
Opportunities
- Expansion into emerging markets.
- Partnerships with law enforcement agencies.
- Development of new testing technologies.
- Focus on home diagnostics market.
Threats
- Competition from larger and more established players.
- Evolving security threats requiring continuous innovation.
- Regulatory changes impacting testing requirements.
- Economic downturn affecting government spending on security.
Competitive Advantages
- Specialized product line focused on niche market.
- Proprietary testing technologies.
- Established relationships with law enforcement agencies.
- Expertise in narcotics and explosives detection.
About IDTA
IDenta Corp., established in 1997 and headquartered in Jerusalem, Israel, operates within the healthcare sector, specifically focusing on medical diagnostics and research. The company develops, manufactures, and supplies field detection and home diagnostics testing kits for narcotics and explosives, along with forensic products. These offerings cater to the homeland security and consumer markets globally. IDenta's product portfolio includes testing kits for drugs, explosives, and bullet holes, as well as FerroPrint testing products, blood detection kits, precursors of drugs test kits, and portable sniffers. The company's solutions are primarily targeted at law enforcement, military, and government agencies, alongside other organizations involved in combating illicit drugs and terrorist threats. IDenta's business model centers around providing rapid and reliable on-site testing solutions, addressing the increasing demand for efficient detection methods in security-sensitive environments. Despite operating in a niche market, IDenta faces competition from larger and more established players in the diagnostics and security sectors. The company's financial performance reflects the challenges of competing in this space, with a negative profit margin of -5.4%.
What They Do
- Develops field detection kits for narcotics and explosives.
- Manufactures home diagnostic testing kits.
- Supplies forensic products for homeland security.
- Offers drug testing kits for law enforcement.
- Provides explosives detection kits for military use.
- Creates bullet-hole testing kits for forensic analysis.
- Produces FerroPrint testing products for crime scene investigation.
- Develops blood detection kits for forensic applications.
Business Model
- Sells detection kits to law enforcement agencies.
- Supplies testing solutions to military and government organizations.
- Distributes forensic products to homeland security markets.
- Generates revenue through direct sales and partnerships.
Industry Context
IDenta Corp. operates in the medical diagnostics and research industry, specifically within the niche market of narcotics and explosives detection. The global market for security screening and detection is driven by increasing security concerns and regulatory requirements. The competitive landscape includes companies like ALID, APPB, CNNA, CPMD, and ENZC, which offer various detection and security solutions. IDenta's focus on field-portable testing kits differentiates it from competitors that may offer more lab-based or stationary solutions. The industry is characterized by technological innovation and evolving threats, requiring companies to continuously adapt and improve their detection capabilities.
Key Customers
- Law enforcement agencies
- Military organizations
- Government agencies
- Homeland security markets
Financials
Chart & Info
IDenta Corp. (IDTA) stock price: Price data unavailable
Latest News
No recent news available for IDTA.
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for IDTA.
Price Targets
Wall Street price target analysis for IDTA.
MoonshotScore
What does this score mean?
The MoonshotScore rates IDTA's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Amichai Glattstein
CEO
Amichai Glattstein serves as the CEO of IDenta Corp., managing a team of 11 employees. His background includes experience in the security and defense industries, with a focus on developing and commercializing innovative technologies. He has a proven track record of leading companies through periods of growth and expansion. His expertise lies in identifying market opportunities, building strategic partnerships, and driving product development.
Track Record: Under his leadership, IDenta Corp. has focused on expanding its product line and strengthening its relationships with key customers. He has overseen the development of new testing kits and the implementation of more efficient manufacturing processes. His strategic decisions have aimed at positioning the company for long-term growth and profitability.
IDTA OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that IDenta Corp. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQB or OTCQX. Companies in this tier often have limited trading volume and may be subject to less regulatory oversight compared to those listed on major exchanges like NYSE or NASDAQ. Investing in companies on the OTC Other tier carries higher risks due to the potential for limited information and greater price volatility.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure
- Low trading volume and liquidity
- Greater price volatility
- Potential for manipulation
- Higher risk of fraud or mismanagement
- Verify the company's financial statements and SEC filings (if any).
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Evaluate the company's revenue and profitability trends.
- Check for any legal or regulatory issues.
- Monitor the company's trading volume and price activity.
- Consult with a financial advisor before investing.
- Established relationships with law enforcement agencies.
- Proprietary testing technologies.
- Focus on a niche market with growing demand.
- CEO with experience in the security and defense industries.
IDTA Healthcare Stock FAQ
What does IDenta Corp. do?
IDenta Corp. specializes in the development, manufacture, and supply of field detection and home diagnostic testing kits, primarily focused on narcotics, explosives, and forensic products. The company caters to law enforcement, military, government agencies, and other organizations involved in combating illicit drugs and terrorist threats. Their product line includes testing kits for drugs, explosives, bullet holes, blood detection, and portable sniffers, offering rapid and reliable on-site testing solutions for security-sensitive environments.
What do analysts say about IDTA stock?
As of 2026-03-15, there is limited analyst coverage for IDTA stock due to its OTC listing and small market capitalization. Key valuation metrics such as the negative P/E ratio of -12.21 reflect the company's current lack of profitability. Growth considerations include potential partnerships with government agencies and expansion into emerging markets. Investors should conduct thorough due diligence and consider the risks associated with OTC stocks before investing.
What are the main risks for IDTA?
IDenta Corp. faces several key risks, including competition from larger and more established players in the diagnostics and security sectors. The company's limited financial resources and negative profit margin pose challenges to its long-term sustainability. Evolving security threats require continuous innovation and adaptation, which can be costly and time-consuming. Regulatory changes impacting testing requirements and market access could also negatively affect the company's business. Additionally, the OTC listing carries inherent risks such as low liquidity and greater price volatility.
What are the key factors to evaluate for IDTA?
IDenta Corp. (IDTA) currently holds an AI score of 56/100, indicating moderate score. Key strength: Specialized product line for narcotics and explosives detection. Primary risk to monitor: Competition from larger and more established players in the diagnostics and security sectors. This is not financial advice.
How frequently does IDTA data refresh on this page?
IDTA prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven IDTA's recent stock price performance?
Recent price movement in IDenta Corp. (IDTA) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Specialized product line for narcotics and explosives detection. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider IDTA overvalued or undervalued right now?
Determining whether IDenta Corp. (IDTA) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying IDTA?
Before investing in IDenta Corp. (IDTA), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited financial data available for comprehensive analysis.
- OTC listing increases investment risk.